Oncolytics Biotech (Oncolytics Biotech) Total Liabilities : $8.39 Mil (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Oncolytics Biotech Total Liabilities?

Oncolytics Biotech's Total Liabilities for the quarter that ended in Dec. 2023 was $8.39 Mil.

Oncolytics Biotech's quarterly Total Liabilities increased from Jun. 2023 ($7.32 Mil) to Sep. 2023 ($12.62 Mil) but then declined from Sep. 2023 ($12.62 Mil) to Dec. 2023 ($8.39 Mil).

Oncolytics Biotech's annual Total Liabilities increased from Dec. 2021 ($7.64 Mil) to Dec. 2022 ($7.97 Mil) and increased from Dec. 2022 ($7.97 Mil) to Dec. 2023 ($8.39 Mil).

Oncolytics Biotech Total Liabilities Historical Data

The historical data trend for Oncolytics Biotech's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncolytics Biotech Total Liabilities Chart

Oncolytics Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

15.01

7.49

7.64

7.97

8.39

Oncolytics Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															7.97	7.00	7.32	12.62	8.39

Oncolytics Biotech Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Oncolytics Biotech's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	3.158	+	(0.216	+	0.0010000000000003
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	5.016	+	0)
	=	8.39

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	28.936	-	20.545
	=	8.39

Oncolytics Biotech's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	3.158	+	(0.216	+	0.0010000000000003
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	5.016	+	0)
	=	8.39

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	28.936	-	20.545
	=	8.39

Oncolytics Biotech Total Liabilities Related Terms

Thank you for viewing the detailed overview of Oncolytics Biotech's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncolytics Biotech (Oncolytics Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (NAS:ONCY) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

ONC:Canada

Address

322 11th Avenue S.W, Suite 804, Calgary, AB, CAN, T2R 0C5

Website

https://www.oncolyticsbiotech.com

Oncolytics Biotech Inc is a development-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. Its clinical development plan has the approval of its products as quickly as possible and expands its products into commercially valuable new treatment areas as objectives. The primary focus is to advance programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies.